Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Clin Pharmacol Ther ; 109(3): 728-738, 2021 03.
Article in English | MEDLINE | ID: mdl-32996592

ABSTRACT

Oral breast cancer prevention medications entail systemic exposure, limiting acceptance by high-risk women. Delivery through the breast skin, although an attractive alternative, requires demonstration of drug distribution throughout the breast. We conducted a randomized double-blind, placebo-controlled phase II clinical trial comparing telapristone acetate, a progesterone receptor antagonist, administered orally (12 mg/day) or transdermally (12 mg/breast) for 4 ± 1 weeks to women planning mastectomy. Plasma and tissue concentrations, measured at five locations in the mastectomy specimen using liquid chromatography tandem mass spectrometry were compared. In 60 evaluable subjects, median drug concentration (ng/g tissue) was 103 (interquartile range (IQR): 46.3-336) in the oral vs. 2.82 (IQR: 1.4-5.5) in the transdermal group. Despite poor dermal permeation, within-breast drug distribution pattern was identical in both groups (R2  = 0.88, P = 0.006), demonstrating that transdermally and orally delivered drug is distributed similarly through the breast, and is strongly influenced by tissue adiposity (P < 0.0001). Other skin-penetrant drugs should be tested for breast cancer prevention.


Subject(s)
Antineoplastic Agents/administration & dosage , Breast Neoplasms/drug therapy , Neoadjuvant Therapy , Norpregnadienes/administration & dosage , Skin Absorption , Adiposity , Administration, Cutaneous , Administration, Oral , Adult , Antineoplastic Agents/adverse effects , Antineoplastic Agents/blood , Breast Neoplasms/blood , Breast Neoplasms/surgery , Chemotherapy, Adjuvant , Chromatography, Liquid , Double-Blind Method , Drug Monitoring , Female , Humans , Mastectomy , Middle Aged , Norpregnadienes/adverse effects , Norpregnadienes/blood , Tandem Mass Spectrometry , Time Factors , Tissue Distribution , Treatment Outcome , United States
2.
Am J Community Psychol ; 67(1-2): 205-219, 2021 03.
Article in English | MEDLINE | ID: mdl-33078861

ABSTRACT

Women of Haitian descent living in the Dominican Republic experience oppression due to their gender, ethnicity, and economic status. They also exhibit high rates of participation in evangelical Christian communities, a paradoxical finding given the restricted roles women have traditionally played in these settings. The goals of this study were to explore the perceived benefits of participation in evangelical communities and the setting characteristics that lead to these benefits. The research team interviewed 19 current and former church participants aged 18-59. Thematic analysis revealed three perceived benefits of congregational life. Participants viewed their participation as: (a) an opportunity for personal growth and development; (b) protective against negative social influences; and (c) providing social support in the face of life challenges. In addition, dependable, expected, and reciprocal relational support was a key characteristic of evangelical communities. Findings extend the current understanding of how religious communities enhance well-being for marginalized women through social support networks. Findings also explore the dialectical nature of settings as both empowering and disempowering. Implications for future interventions are discussed.


Subject(s)
Ethnicity , Social Support , Dominican Republic , Female , Haiti , Humans , Socioeconomic Factors
3.
Cancer Prev Res (Phila) ; 13(1): 117-126, 2020 01.
Article in English | MEDLINE | ID: mdl-31619442

ABSTRACT

The Chinese natural product, berberine, has biological properties that support its potential efficacy as a colon cancer prevention agent. Its longstanding use in China to treat gastrointestinal tract and rheumatologic disorders is generally regarded as safe, supporting initial investigations in an at-risk population, such as individuals with ulcerative colitis. However, the safety of berberine in this population is not established. Individuals living in China with biopsy-proven ulcerative colitis, ≤grade 2 dysplasia, and with a ulcerative colitis disease activity index (UCDAI) score ≤1 on mesalamine, were randomized 3:1 in a double-blind phase I trial to berberine 900 mg/day or placebo for 3 months, with the primary objective of assessing safety. Blood samples and biopsies of the colorectum, from prespecified locations, were collected prior to and following therapy. Secondary endpoints included changes in UCDAI score, and in tissue and plasma markers of inflammation. Of toxicities at least possibly related, one episode of grade 3 elevation in transaminases and one episode of grade 1 nausea were observed among 12 individuals on berberine, and none were observed among 4 on placebo. The mean plasma berberine concentration was 3.5 nmol/L after berberine treatment, significantly higher than 0.5 nmol/L with placebo. Berberine significantly decreased the Geboes grade in colonic tissue, but had a nonsignificant effect on other tissue or blood biomarkers related to cell growth and inflammation. The combination of berberine and mesalamine is well tolerated in Chinese with ulcerative colitis and may enhance mesalamine's anti-inflammatory effects in colonic tissue.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/adverse effects , Berberine/adverse effects , Colitis, Ulcerative/drug therapy , Colorectal Neoplasms/prevention & control , Administration, Oral , Adult , Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Anti-Inflammatory Agents, Non-Steroidal/pharmacokinetics , Berberine/administration & dosage , Berberine/pharmacokinetics , Biopsy , China , Colitis, Ulcerative/diagnosis , Colitis, Ulcerative/immunology , Colitis, Ulcerative/pathology , Colon/drug effects , Colon/immunology , Colon/pathology , Colorectal Neoplasms/immunology , Colorectal Neoplasms/pathology , Double-Blind Method , Drug Synergism , Drug Therapy, Combination , Female , Humans , Intestinal Mucosa/drug effects , Intestinal Mucosa/immunology , Intestinal Mucosa/pathology , Male , Mesalamine/administration & dosage , Mesalamine/adverse effects , Mesalamine/pharmacokinetics , Middle Aged , Prospective Studies , Rectum/drug effects , Rectum/immunology , Rectum/pathology , Severity of Illness Index , Tissue Distribution , Young Adult
4.
PLoS One ; 13(4): e0193544, 2018.
Article in English | MEDLINE | ID: mdl-29617381

ABSTRACT

Chemoprevention represents an attractive modality against colorectal cancer (CRC) although widespread clinical implementation of promising agents (e.g. aspirin/NSAIDS) have been stymied by both suboptimal efficacy and concerns over toxicity. This highlights the need for better agents. Several groups, including our own, have reported that the over-the-counter laxative polyethylene glycol (PEG) has remarkable efficacy in rodent models of colon carcinogenesis. In this study, we undertook the first randomized human trial to address the role of PEG in prevention of human colonic neoplasia. This was a double-blind, placebo-controlled, three-arm trial where eligible subjects were randomized to 8g PEG-3350 (n = 27) or 17g PEG-3350 (n = 24), or placebo (n = 24; maltodextrin) orally for a duration of six months. Our initial primary endpoint was rectal aberrant crypt foci (ACF) but this was changed during protocol period to rectal mucosal epidermal growth factor receptor (EGFR). Of the 87 patients randomized, 48 completed study primary endpoints and rectal EGFR unchanged PEG treatment. Rectal ACF had a trend suggesting potentially reduction with PEG treatment (pre-post change 1.7 in placebo versus -0.3 in PEG 8+ 17g doses, p = 0.108). Other endpoints (proliferation, apoptosis, expression of SNAIL and E-cadherin), previously noted to be modulated in rodent models, appeared unchanged with PEG treatment in this clinical trial. We conclude that PEG was generally well tolerated with the trial failing to meet primary efficacy endpoints. However, rectal ACFs demonstrated a trend (albeit statistically insignificant) for suppression with PEG. Moreover, all molecular assays including EGFR were unaltered with PEG underscoring issues with lack of translatability of biomarkers from preclinical to clinical trials. This data may provide the impetus for future clinical trials on PEG using more robust biomarkers of chemoprevention. TRIAL REGISTRATION: ClinicalTrials.gov NCT00828984.


Subject(s)
Aberrant Crypt Foci/prevention & control , Anticarcinogenic Agents/therapeutic use , Colorectal Neoplasms/prevention & control , ErbB Receptors/analysis , Laxatives/therapeutic use , Polyethylene Glycols/therapeutic use , Aberrant Crypt Foci/pathology , Adult , Aged , Aged, 80 and over , Anticarcinogenic Agents/administration & dosage , Biomarkers, Tumor/analysis , Chemoprevention , Colonic Neoplasms/pathology , Colonic Neoplasms/prevention & control , Colorectal Neoplasms/pathology , Double-Blind Method , Female , Humans , Laxatives/administration & dosage , Male , Middle Aged , Placebo Effect , Polyethylene Glycols/administration & dosage , Rectum/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...